TABLE 1.
Serum RSV neutralizing titers, ELISA titers and protection in mice immunized with recombinant VSVa
| Virusf | Serum neutralizing titerb | RSV ELISA titerc | Protectiond |
|---|---|---|---|
| Pre-immune | <1:8 | NDe | ND |
| VSV rwt | <1:8 | <64 | − |
| VSV-RSV G | 1:16 | 128 | + |
| VSV-RSV F | 1:32 | 4,096 | + |
| VSVΔG | <1:8 | <64 | − |
| VSVΔG-RSV G | <1:8 | <64 | − |
| VSVΔG-RSV F | <1:8 | 1,024 | + |
| Human anti-RSV | 1:1,024 | ND | ND |
| MAbαF | ND | 4,096 | ND |
a
Serum was collected 2 weeks after boost immunizations.
b
Neutralizing titers were determined on Vero cells and are reported as the last dilution in which RSV CPE were absent. RSV-specific antiserum (human anti-RSV serum) was used as a positive control.
c
Dilution of pooled mouse serum which corresponded to an OD450 of 0.5.
d
Protection against RSV replication in BAL fluid and lung tissue.
e
ND, not determined.
f
rwt, recombinant wild type; MAbaF, RSV F-specific mouse monoclonal antibody.